Deborah Charych, Ph.D.

Deborah Charych, Ph.D., is a prominent figure in the biotechnology and pharmaceutical industries, currently serving as the Scientific Founder, Chief Technology/Science Officer, and Advisor at RayzeBio. She has over 20 years of experience, particularly in oncology and drug development.

Professional Background

Dr. Charych co-founded RayzeBio, a company focused on the targeted delivery of radionuclides for cancer treatment. Under her leadership as Chief Technology Officer, she was instrumental in developing the scientific and operational R&D strategy, which facilitated a successful $45 million Series A financing and subsequent funding rounds totaling $418 million. Her work at RayzeBio emphasizes innovative approaches to delivering therapeutic radioisotopes, particularly Actinium-225, to solid tumors.12

Before her tenure at RayzeBio, Dr. Charych held significant roles at various biotech firms. At Nektar Therapeutics, she led the preclinical and early clinical development of an immuno-oncology pipeline, culminating in a substantial deal with Bristol Myers Squibb valued at $1.8 billion. Additionally, her experience includes leadership positions at FivePrime Therapeutics and Chiron Corporation, where she contributed to oncology target discovery and the development of biologics for cancer and autoimmune diseases.13

Academic Credentials

Dr. Charych earned her Ph.D. in Chemistry from the University of California, Berkeley, and holds a B.S. in Chemistry from Carnegie Mellon University. Her academic background has provided her with a strong foundation in cancer biology, immunology, and chemistry, which she has applied throughout her career in both academia and industry.13

Current Roles

In addition to her role at RayzeBio, Dr. Charych has been appointed to the board of Skye Bioscience, further extending her influence in the biotech sector. Her expertise in scientific leadership and drug development continues to shape advancements in targeted cancer therapies.45